Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -30.00 -2.97% 980.00 970.00 990.00 1,010.00 955.00 1,010.00 259,734 16:21:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 728

MaxCyte, Inc. Participation in Upcoming Investor Conferences

23/02/2021 7:00am

RNS Non-Regulatory


MaxCyte, Inc.

22 February 2021


MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows:

Cowen 41st Annual Health Care Conference

Who: Doug Doerfler, President & Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will present a corporate overview

Dates: Virtual conference March 1 - 4, 2021

MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET

An archived version of the presentation will be made available following the conference in the Investors section of the Company website

H.C. Wainwright & Co Global Life Sciences Conference

Who: Doug Doerfler, President & Chief Executive Officer, will present a corporate overview

Dates: Virtual conference March 9 - 10, 2021

MaxCyte Presentation Details: Available on demand to conference participants March 9 - 10, 2021

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering platform technology and is responsible for helping to bring next--generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit .

For further information, please contact:

    MaxCyte Inc. 
    Doug Doerfler, Chief Executive 
    Amanda Murphy, Chief Financial 
    Officer                            +1 301-944-1660 
 Nominated Adviser and Joint 
  Panmure Gordon 
  Emma Earl / Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                        +44 (0)20 7886 2500 
 Joint Corporate Brokers 
  Numis Securities Limited 
  James Black / Duncan Monteith / 
  Matthew O'Dowd                        +44 (0)20 7260 1000 
 Stifel Nicolaus Europe Limited 
  Healthcare Investment Banking 
  Nicholas Moore / Ben Maddison / 
  Samira Essebiyea 
  Corporate Broking 
  Nick Adams                            +44 (0) 20 7710 7600 
 Financial PR Adviser 
  Consilium Strategic                  +44 (0)203 709 5700 
  Communications                       maxcyte@consilium-comms. 
  Mary-Jane Elliott / Chris Welsh      com 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 23, 2021 02:00 ET (07:00 GMT)

1 Year Maxcyte Chart

1 Year Maxcyte Chart

1 Month Maxcyte Chart

1 Month Maxcyte Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210227 13:35:15